134 related articles for article (PubMed ID: 22255166)
1. Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies.
Baas T; Gräfe K; Khawaja A; Dössel O
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3796-9. PubMed ID: 22255166
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
3. Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin.
Couderc JP; McNitt S; Hyrien O; Vaglio M; Xia X; Polonsky S; Moss AJ; Zareba W
Drug Saf; 2008; 31(3):249-60. PubMed ID: 18302449
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin-induced torsades de pointes.
Sherazi S; DiSalle M; Daubert JP; Shah AH
Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
[TBL] [Abstract][Full Text] [Related]
5. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin and torsade de pointes.
Dale KM; Lertsburapa K; Kluger J; White CM
Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
[TBL] [Abstract][Full Text] [Related]
7. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
8. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
[TBL] [Abstract][Full Text] [Related]
9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
10. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
11. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.
Bloomfield DM; Kost JT; Ghosh K; Hreniuk D; Hickey LA; Guitierrez MJ; Gottesdiener K; Wagner JA
Clin Pharmacol Ther; 2008 Oct; 84(4):475-80. PubMed ID: 19238652
[TBL] [Abstract][Full Text] [Related]
12. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
13. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Frothingham R
Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
[TBL] [Abstract][Full Text] [Related]
14. Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.
Couderc JP; Garnett C; Li M; Handzel R; McNitt S; Xia X; Polonsky S; Zareba W
Ann Noninvasive Electrocardiol; 2011 Jan; 16(1):13-24. PubMed ID: 21251129
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin does increase the corrected QT interval.
White CM; Grant EM; Quintiliani R
Clin Infect Dis; 2001 Oct; 33(8):1441-4. PubMed ID: 11565091
[No Abstract] [Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
[TBL] [Abstract][Full Text] [Related]
17. Update on the cardiac safety of moxifloxacin.
Haverkamp W; Kruesmann F; Fritsch A; van Veenhuyzen D; Arvis P
Curr Drug Saf; 2012 Apr; 7(2):149-63. PubMed ID: 22873499
[TBL] [Abstract][Full Text] [Related]
18. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
19. Statistical characteristics of moxifloxacin-induced QTc effect.
Yan LK; Zhang J; Ng MJ; Dang Q
J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
[TBL] [Abstract][Full Text] [Related]
20. T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.
Couderc JP; Xia X; Peterson DR; McNitt S; Zhao H; Polonsky S; Moss AJ; Zareba W
Heart Rhythm; 2011 Jul; 8(7):1036-43. PubMed ID: 21315844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
